Serum apelin levels: Clinical association with vascular involvements in patients with systemic sclerosis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages 37-42

  Aozasa, N ^a   Asano, Y ^a   Akamata, K ^a   Noda, S ^a   Masui, Y ^a   Yamada, D ^a   Tamaki, Z ^a   Tada, Y ^a   Sugaya, M ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN;

ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCLERODERMA; SKIN ULCER; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84872845814     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04354.x     Document Type: Article

References (28)

1. Distler JH, Gay S, Distler O,. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006; 45: iii26-iii27.
2. Manetti M, Guiducci S, Ibba-Manneschi L, et al. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010; 14: 1241-1254.
3. Koch AE, Distler O,. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007; 9: S3.
4. Kleinz MJ, Davenport AP,. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198-211.
5. Kleinz MJ, Davenport AP,. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004; 118: 119-125.
6. Takakura N, Kidoya H,. Maturation of blood vessels by haematopoietic stem cells and progenitor cells: involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation. Thromb Haemost 2009; 101: 999-1005.
7. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99: 87-92.
8. Falcao-Pires I, Ladeiras-Lopes R, Leite-Moreira AF,. The apelinergic system: a promising therapeutic target. Expert Opin Ther Targets 2010; 14: 633-645.
9. Kasai A, Shintani N, Kato H, et al. Retardation of retinal vascular development in apelin-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 1717-1722.
10. Melgar-Lesmes P, Casals G, Pauta M, et al. Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 2010; 151: 5306-5314.
11. Siddiquee K, Hampton J, Khan S, et al. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 2011; 29: 724-731.
12. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
14. Asano Y, Ihn H, Yamane K, et al. The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 204-210.
15. Masui Y, Asano Y, Shibata S, et al.,. Serum adiponectin levels correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2011; doi: 10.1111/j.1468-3083.2011.04077.x. [Epub ahead of print].
16. Matsushita T, Hasegawa M, Hamaguchi Y, et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-284.
17. Steen V, Medsger TA Jr,. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-522.
18. Yokomori H, Oda M, Yoshimura K, et al. Overexpression of apelin receptor (APJ/AGTRL1) on hepatic stellate cells and sinusoidal angiogenesis in human cirrhotic liver. J Gastroenterol 2011; 46: 222-231.
19. Melgar-Lesmes P, Pauta M, Reichenbach V, et al., Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut 2011; 60: 1404-1411.
20. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-1998.
21. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 2008; 3: e1452.
22. Rajkumar VS, Sundberg C, Abraham DJ, et al. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 1999; 42: 930-941.
23. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-581.
24. Hasegawa M, Nagai Y, Tamura A, et al. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006; 155: 1159-1164.
25. Stafford L, Englert H, Gover J, et al. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 1998; 57: 476-479.
26. Guiducci S, Distler O, Distler JH, et al. Mechanisms of vascular damage in SSc-implications for vascular treatment strategies. Rheumatology (Oxford) 2008; 47: v18-v20.
27. Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 2008; 103: 432-440.
28. Ouchi N, Walsh K,. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.